During the past decade, Department of Pulmonology Semmelweis University conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Department of Pulmonology Semmelweis University" #1 sponsor was "University of Pecs" with 2 trials, followed by "Actelion" with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored, "Eisai Inc." with 1 trials sponsored and "FibroGen" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Department of Pulmonology Semmelweis University" #1 collaborator was "HECRIN Consortium" with 2 trials as a collaborator, "Hungarian Ministry of Innovation and Technology" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Department of Pulmonology Semmelweis University" are "SARS-CoV-2 Infection" (2 trials), "Idiopathic Pulmonary Fibrosis" (1 trials), "Metastatic Non Small Cell Lung Cancer" (1 trials), "Non-small Cell Lung Cancer" (1 trials) and "Pulmonary Arterial Hypertension" (1 trials). Many other conditions were trialed in "Department of Pulmonology Semmelweis University" in a lesser frequency.

Most popular intervention types in "Department of Pulmonology Semmelweis University" are "Drug" (5 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "ACT-293987 (NS-304)" (1 trials), "Datopotamab Deruxtecan" (1 trials), "Favipiravir" (1 trials), "Pamrevlumab" (1 trials) and "Pembrolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Department of Pulmonology Semmelweis University" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Department of Pulmonology Semmelweis University". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Department of Pulmonology Semmelweis University, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Department of Pulmonology Semmelweis University, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".